Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
But: Considering these are prescription drugs, not over-the-counter wellness buys, choosing the right provider mattersand not every service offering GLP-1s actually supports safe, supervised microdosing
This determines which drugs are covered, whether they have prior authorization or quantity limit requirements, and how much coverage the plan will issue
I've been on it for a year, and I've lost about 70 pounds
Insulin Resistance: GLP-1 meds improve insulin sensitivity, but stopping them can tip the balance
Consequently, only about 1020% of total plasma GLP-1 remains in its biologically active form, with the majority rapidly inactivated by DPP-IV [12]